Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juliette Randerson-Moor

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
The Lancet. Oncology|January 2, 2007
Management of familial melanomaJulia Newton Bishop, Mark Harland, Juliette Randerson-Moor, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 15, 2006
GSTM1 and CYP1A1 polymorphisms, tobacco, air pollution, and lung cancer: a study in rural ThailandPaola Pisani, Petcharin Srivatanakul, Juliette Randerson-Moor, et al.
Clinical Nutrition (Edinburgh, Scotland)|May 15, 2013
Do vitamin A serum levels moderate outcome or the protective effect of vitamin D on outcome from malignant melanoma?Sinead Field, Faye Elliott, Juliette Randerson-Moor, et al.
International Journal of Cancer|November 19, 2014
25-Hydroxyvitamin D2 /D3 levels and factors associated with systemic inflammation and melanoma survival in the Leeds Melanoma CohortJulia A Newton-Bishop, John R Davies, Faheem Latheef, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 13, 2005
No Evidence for BRAF as a melanoma/nevus susceptibility geneSharon Jackson, Mark Harland, Faye Turner, et al.
Oncotarget|April 9, 2016
Changes in plasma chemokine C-C motif ligand 2 levels during treatment with eicosapentaenoic acid predict outcome in patients undergoing surgery for colorectal cancer liver metastasisMilene Volpato, Sarah L Perry, Gemma Marston, et al.
The Journal of Investigative Dermatology|March 11, 2004
An assessment of a variant of the DNA repair gene XRCC3 as a possible nevus or melanoma susceptibility genotypeChandra Gooptu Bertram, Rupert M Gaut, Jennifer H Barrett, et al.
The Journal of Investigative Dermatology|April 7, 2024
Systemic Inflammation, the Peripheral Blood Transcriptome, and Primary MelanomaJuliette Randerson-Moor, John Davies, Mark Harland, et al.
Scientific Reports|June 22, 2019
High-Resolution Copy Number Patterns From Clinically Relevant FFPE MaterialAnastasia Filia, Alastair Droop, Mark Harland, et al.
Pigment Cell & Melanoma Research|October 30, 2019
MX 2 is a novel regulator of cell cycle in melanoma cellsMarina Juraleviciute, Joanna Pozniak, Jérémie Nsengimana, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
The Lancet. Oncology|January 2, 2007
Management of familial melanomaJulia Newton Bishop, Mark Harland, Juliette Randerson-Moor, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 15, 2006
GSTM1 and CYP1A1 polymorphisms, tobacco, air pollution, and lung cancer: a study in rural ThailandPaola Pisani, Petcharin Srivatanakul, Juliette Randerson-Moor, et al.
Clinical Nutrition (Edinburgh, Scotland)|May 15, 2013
Do vitamin A serum levels moderate outcome or the protective effect of vitamin D on outcome from malignant melanoma?Sinead Field, Faye Elliott, Juliette Randerson-Moor, et al.
International Journal of Cancer|November 19, 2014
25-Hydroxyvitamin D2 /D3 levels and factors associated with systemic inflammation and melanoma survival in the Leeds Melanoma CohortJulia A Newton-Bishop, John R Davies, Faheem Latheef, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 13, 2005
No Evidence for BRAF as a melanoma/nevus susceptibility geneSharon Jackson, Mark Harland, Faye Turner, et al.
Oncotarget|April 9, 2016
Changes in plasma chemokine C-C motif ligand 2 levels during treatment with eicosapentaenoic acid predict outcome in patients undergoing surgery for colorectal cancer liver metastasisMilene Volpato, Sarah L Perry, Gemma Marston, et al.
The Journal of Investigative Dermatology|March 11, 2004
An assessment of a variant of the DNA repair gene XRCC3 as a possible nevus or melanoma susceptibility genotypeChandra Gooptu Bertram, Rupert M Gaut, Jennifer H Barrett, et al.
The Journal of Investigative Dermatology|April 7, 2024
Systemic Inflammation, the Peripheral Blood Transcriptome, and Primary MelanomaJuliette Randerson-Moor, John Davies, Mark Harland, et al.
Scientific Reports|June 22, 2019
High-Resolution Copy Number Patterns From Clinically Relevant FFPE MaterialAnastasia Filia, Alastair Droop, Mark Harland, et al.
Pigment Cell & Melanoma Research|October 30, 2019
MX 2 is a novel regulator of cell cycle in melanoma cellsMarina Juraleviciute, Joanna Pozniak, Jérémie Nsengimana, et al.
Pageof 3